Traditional Chinese medicine composition for preventing or treating hyperuricemia and its application

Abstract

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition and application for preventing or treating hyperuricemia. Background Art

[0002] Hyperuricemia (HUA) is a chronic metabolic disease caused by impaired purine metabolism. In recent years, with improved living standards, the prevalence of HUA has steadily increased, becoming the fourth most common disease after hypertension, hyperlipidemia, and hyperglycemia, posing a serious threat to human health. HUA harms multiple body systems, most commonly affecting joints, leading to acute and chronic gouty arthritis, tophi, and joint deformities. Uric acid crystals can form urinary stones, disrupting renal tubular function and causing uric acid nephropathy, and in severe cases, renal failure. HUA can affect endothelial metabolism, exacerbating atherosclerosis and inducing coronary heart disease. HUA is an independent risk factor for vascular dementia and cognitive decline. It can also exacerbate diabetes and its chronic complications. Therefore, the timely and appropriate use of urate-lowering medications is essential to reduce uric acid deposition, mitigate gout attacks, alleviate cardiac damage, and minimize the risk of other complications.

[0003] Current treatment options primarily include drugs that inhibit uric acid synthesis, primarily allopurinol and febuxostat. These drugs can rapidly reduce the source of uric acid, but they are associated with adverse reactions such as gastrointestinal symptoms, rashes, liver damage, bone marrow suppression, skeletal muscle and connective tissue symptoms, and potentially fatal hypersensitivity reactions. Drugs that increase uric acid excretion, primarily benzbromarone and probenecid, should be used with caution in patients with urinary tract stones, hepatic and renal insufficiency, gastrointestinal ulcers, the elderly, and children. These drugs present significant clinical inconsistencies. Medication compliance in HUA, particularly in patients with asymptomatic HUA, is extremely low, which reduces the effectiveness of drug treatment. Urate oxidase analogs, primarily including purikaxib and rasburicase, are biologics that catalyze the conversion of slightly water-soluble uric acid to the highly water-soluble allantoin. Among them, Prekysib is a pegylated urate oxidase that can effectively lower serum uric acid, reduce uric acid crystal deposition, and promote the dissolution of tophi. However, its high price, short half-life, immunogenicity, and susceptibility to hypersensitivity reactions have resulted in suboptimal treatment outcomes in 40% of subjects. While these drugs have demonstrated some effectiveness in the treatment of HUA, real-world studies have found that HUA patients face numerous clinical limitations, including poor medication compliance (only 36.8% of patients have good compliance) and rebound serum uric acid levels after discontinuation, due to the combined effects of drug side effects and the insidious nature of HUA symptoms. Therefore, finding safe and effective drugs for the prevention and treatment of hyperuricemia is an urgent issue.

[0004] While Traditional Chinese Medicine (TCM) doesn't have names for conditions like "hyperuricemia" or "gout," gout can be categorized as "gout," "heat arthralgia," or "white tiger and calamity" based on its etiology, pathogenesis, and clinical manifestations. Treatment primarily focuses on clearing heat and dampness, and tonifying the kidneys and spleen. Hyperuricemia has a complex pathogenesis, and TCM offers significant advantages in treating this condition. Herbs and their compound formulas, which combine medicinal properties with food and are highly safe, offer multiple ingredients and procedures, making them particularly suitable for the prevention and treatment of this complex, lifestyle-related condition. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to provide a new option for treating patients with hyperuricemia.

[0006] The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia and kidney damage, comprising the following ingredients: extracts of thistle, gardenia, bamboo leaves, Chinese angelica, lily, corn silk, broccoli seed, and eucommia leaf. Hyperuricemia is caused by inadequate endowment, an irregular diet, invasion of external pathogens such as dampness and heat, or the mutual obstruction of phlegm and blood stasis, which blocks the meridians and joints, leading to poor circulation of qi and blood. Treatment should be based on clearing heat and dampness, cooling blood, activating blood circulation, and tonifying the kidneys. In the formula, thistle is sweet and cool, entering the blood, and is good at clearing heat and cooling blood, as well as promoting diuresis and relieving stranguria. Gardenia, bamboo leaves, and corn silk clear heat and purge fire, promoting diuresis and relieving stranguria. Lily nourishes the heart and moistens the lungs, replenishes yin and clears heat, and prevents other herbs from clearing heat and damaging yin. Broccoli seed extract lowers qi and resolves phlegm. Eucommia leaf tonifies the liver and kidneys, strengthening the tendons and bones. Chinese angelica nourishes and harmonizes blood, guiding blood back to the meridians, and preventing other herbs from causing cold and stagnant blood. Taken together, these herbs form a formula that clears heat and dampness, reduces acid and protects the kidneys, and cools blood and activates blood circulation. The Chinese medicinal ingredients in the prescription contain chemical components such as cyclopentane ether terpenes, flavonoids, and triterpenes, which have anti-inflammatory, antioxidant, kidney and liver protection effects, and can simultaneously inhibit uric acid synthesis, lower blood uric acid levels, promote uric acid excretion, inhibit inflammation, and improve liver and kidney damage. It is effective in preventing or treating hyperuricemia and kidney damage.

[0007] The weight ratio of each component is: 3 to 30 parts of chicory, 1 to 20 parts of gardenia, 1 to 20 parts of bamboo leaves, 3 to 20 parts of angelica, 3 to 30 parts of lily, 1 to 20 parts of corn silk, 0.1 to 20 parts of broccoli seed extract and 1 to 30 parts of eucommia leaves.

[0008] Preferably, the weight ratio of each component is: 4.5 parts of chicory, 3 parts of gardenia, 3 parts of bamboo leaves, 3 parts of angelica, 4.5 parts of lily, 3 parts of corn silk, 3 parts of broccoli seed extract and 6 parts of eucommia leaves.

[0009] The present invention also provides a preparation method of the traditional Chinese medicine composition, comprising the following steps: adding water to thistle, gardenia, bamboo leaves, angelica, lily, corn silk, and eucommia leaves, heating and refluxing extraction twice, filtering, combining the extracts, drying and crushing, and mixing with broccoli seed extract for standby use.

[0010] Furthermore, during the extraction process, the mass-to-volume ratio of the material to the liquid (g / mL) is 1:3 to 1:20.

[0011] Preferably, the mass-to-volume ratio of the feed to the liquid (g / mL) is 1:10.

[0012] Specifically, each extraction time is 1 to 3 hours.

[0013] Preferably, each extraction time is 1 hour.

[0014] The present invention also provides a traditional Chinese medicine composition obtained by the above preparation method.

[0015] The present invention also provides use of the above-mentioned traditional Chinese medicine composition in preparing a medicine for treating or preventing hyperuricemia.

[0016] The present invention also provides the use of the above-mentioned traditional Chinese medicine composition in preparing a medicine for treating or preventing hyperuricemia kidney damage.

[0017] Among them, the application is the use of the above-mentioned traditional Chinese medicine composition in the preparation of drugs for lowering uric acid levels, improving renal dysfunction caused by hyperuricemia, lowering inflammatory factor levels, reducing renal fibrosis caused by hyperuricemia and / or improving liver function.

[0018] Furthermore, the inflammatory factors are IL-1β, IL-6 and TNF-α.

[0019] The present invention also provides a medicine, food or health product for treating or preventing hyperuricemia, comprising the above-mentioned Chinese medicine composition.

[0020] The present invention also provides a medicine, food or health product for treating or preventing hyperuricemia renal damage, comprising the above-mentioned Chinese medicine composition.

[0021] In particular, the above-mentioned medicine also includes pharmaceutically acceptable adjuvants.

[0022] Further, the auxiliary agent is dextrin, sugar or starch.

[0023] Furthermore, the dosage form of the drug is tablets, injections, capsules, pills or granules.

[0024] Particularly, the food is at least one of fresh food, air-dried food, freeze-dried food, compressed candy, solid beverage, liquid beverage, canned food or salted food.

[0025] Beneficial effects of the present invention: The present invention combines clinical practice, adds and subtracts on the basis of the classic prescription Xiaoji Yinzi, and continuously optimizes it to form a fixed prescription for the treatment of hyperuricemia. It is composed of Xiaoji, Gardenia, Bamboo Leaves, Angelica, Lilium, Corn Silk, Broccoli Seed Extract, and Eucommia Leaf. It has the effects of clearing heat and dampness, reducing acid and protecting the kidneys, cooling blood and activating blood circulation. It is clinically used for the prevention and treatment of hyperuricemia and gout, with significant effects and high safety. In order to further explore its effect characteristics, by constructing a hyperuricemia animal model, the effects of this prescription on multiple links of hyperuricemia, including uric acid synthesis, uric acid excretion, xanthine oxidase and its protective effect on kidney damage and liver damage were studied. The results showed that this prescription can inhibit liver xanthine oxidase, reduce blood uric acid, blood creatinine, blood urea nitrogen and urine protein levels, increase urine uric acid levels, reduce serum IL-1β, IL-6, TNF-α levels and kidney F4 / 80 and FN expression, and have no effect on liver function indicators AST and ALT. The results show that the traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, inhibiting xanthine oxidase, improving kidney damage and protecting the liver. It can be used to prevent and treat hyperuricemia, protect the kidney and liver, and provide a basis for further development of the traditional Chinese medicine composition into a food, health product or medicine for preventing or treating hyperuricemia. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 .HE staining of kidneys of mice in each group (20×).

[0027] Figure 2 .F4 / 80 staining images of kidneys of mice in each group (20×).

[0028] Figure 3 .Masson staining of kidneys of mice in each group (20×).

[0029] Figure 4 Fibronectin staining of kidneys of mice in each group (20×).

[0030] Figure 5 α-SMA staining images of kidneys of mice in each group (20×).

[0031] Figure 6 .HE staining of the liver of mice in each group (10×). DETAILED DESCRIPTION

[0032] The main reagents and materials used in the following examples are:

[0033] KM mice were purchased from Zhuhai Baishitong Laboratory Animal Co., Ltd.; medicinal materials were purchased from Guangdong Medicinal Materials Company, and broccoli seed extract was purchased from Ganzhou Huahan Biotechnology Co., Ltd.; potassium oxonate (CAS No. 2207-75-2), hypoxanthine (CAS No. 68-94-0), and allopurinol (CAS No. 315-30-0) were purchased from Shanghai Yuanye Biotechnology Co., Ltd. Uric acid, XOD enzyme, creatinine, urea nitrogen, urine protein, ALT, and AST detection kits were purchased from Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.; IL-1β, IL-6, and TNF-α detection kits were purchased from Jiangsu Enzyme Immunity Industry Co., Ltd.

[0034] Example 1 Preparation of the Chinese medicine composition of the present invention

[0035] Take 4.5g of thistle, 3g of gardenia, 3g of bamboo leaves, 3g of Chinese angelica, 4.5g of lily, 3g of corn silk, 3g of broccoli seed extract, and 6g of Eucommia ulmoides leaf. Add 10 times the amount of water to thistle, gardenia, bamboo leaves, Chinese angelica, lily, corn silk, and Eucommia ulmoides leaf, heat and reflux and extract twice for 1 hour each time. Filter, combine the extracts, dry and grind, add the broccoli seed extract, mix thoroughly, and set aside.

[0036] Example 2 Application of the Chinese medicine composition of the present invention

[0037] The mice were divided into blank control group (Control), model group (Model), allopurinol group (AP, 10 mg / kg / d), low-dose compound group (FL, 5.3 g / kg / d), and high-dose compound group (FH, 10.6 g / kg / d) according to their body weight using a random number table method, with 6 mice in each group.

[0038] 7-8 week old male KM mice were fed with a normal diet and given normal drinking water. After one week of adaptive feeding, mice in the control group were gavaged with 0.5% CMC-Na (0.1 mL / 10 g) and intraperitoneally injected with PBS (0.1 mL / 10 g) daily. The remaining groups were given intraperitoneally injected with potassium oxonate (200 mg / kg / d) and gavaged with hypoxanthine (500 mg / kg / d). At the same time, the allopurinol group was gavaged with allopurinol (10 mg / kg / d). The FL and FH groups were given 5.3 g / kg / d and 10.6 g / kg / d of the compound extract (the Chinese medicine composition prepared in Example 1) at a dosage of 0.1 mL / 10 g for 21 days. After 21 days, the mice were placed in metabolic cages to collect urine for 24 hours. All groups were fasted for 24 hours but not water, anesthetized with isoflurane, and blood was collected by enucleation. After blood was collected, the mouse heart was perfused with 30 mL of normal saline. After perfusion, the kidneys and liver were removed in sequence.

[0039] Indicator Assays: Serum uric acid and liver XOD enzyme levels were measured according to the instructions of the uric acid and XOD enzyme assay kits. Creatinine, urea nitrogen, and urine protein were measured according to the instructions of the creatinine, urea nitrogen, and urine protein assay kits to assess renal function. The levels of inflammatory factors IL-1β, IL-6, and TNF-α were measured according to the instructions of the IL-1β, IL-6, and TNF-α assay kits to assess the level of renal inflammation in the mice. ALT and AST were measured according to the instructions of the ALT and AST assay kits to assess liver function. Histopathology: Kidney and liver tissues were collected and fixed in 4% paraformaldehyde for 24 hours. After dehydration, they were embedded in paraffin blocks and cut into 4-μm sections. The sections were oven-dried at 65°C for 1 hour. After gradient dewaxing with organic reagents, they were stained with hematoxylin and eosin, Masson staining, and immunohistochemistry to observe histopathological changes, inflammatory infiltration, and the degree of fibrosis.

[0040] GraphPad Prism 9.4.1 software was used for data analysis and plotting. Two-group comparisons were performed using a two-tailed unpaired t-test, and multiple group comparisons were performed using one-way ANOVA with Tukey's multiple comparison test. Data are presented as mean ± standard error. P < 0.05 indicates that the difference is statistically significant.

[0041] Experimental results:

[0042] 1. Improve hyperuricemia

[0043] The uric acid levels of mice in each group are shown in Table 1. Compared with the blank control group, the serum uric acid and XOD enzyme levels in the model group were significantly increased, and the urine uric acid level was significantly decreased. After drug intervention, the serum uric acid level was significantly decreased, while the urine uric acid level was significantly increased, and the liver xanthine oxidase level was significantly decreased, indicating that this prescription can significantly improve hyperuricemia.

[0044] Table 1. Statistics of uric acid metabolism indicators in each group

[0045]

[0046] Note: Compared with the blank group: ** P<0.01, *** P<0.001, **** P < 0.0001;

[0047] Compared with the model group: △ P<0.05, △△ P<0.01, △△△△ P<0.0001.

[0048] 2. Improve renal dysfunction caused by hyperuricemia

[0049] (1) Results of routine biochemical indices of renal function

[0050] The results of renal function-related index tests are shown in Table 2. In the model group, the levels of blood urea nitrogen and 24-hour urine protein were significantly increased, and the endogenous creatinine clearance rate was significantly decreased. However, all drug-treated groups were able to reduce the levels of blood urea nitrogen and 24-hour urine protein and increase the endogenous creatinine clearance rate.

[0051] Table 2. Statistical table of renal function indicators in each group

[0052]

[0053]

[0054] Note: Compared with the blank group: *** P<0.001, **** P<0.0001; compared with the model group: △ P<0.05, △△ P<0.01, △△△ P<0.001.

[0055] (2) HE staining results

[0056] By HE staining ( Figure 1 ) observed that the renal tubular cells of the mice in the Control group were normal in morphology and there was no obvious infiltration in the kidneys, while the mice in the Model group showed severe renal damage, with loose and disordered renal tubular structure, glomerular atrophy and other obvious morphological changes. The compound drug administration group, especially the high-dose group, could significantly improve this lesion.

[0057] 3. Improve inflammation levels in mice with high uric acid levels

[0058] (1) Levels of inflammatory factors

[0059] The results of serum inflammatory factor level detection are shown in Table 3. The levels of IL-1β, IL-6 and TNF-α in the model group were significantly increased compared with the blank group, while the levels of IL-1β, IL-6 and TNF-α in the compound administration group were significantly decreased, indicating that the compound can improve the inflammatory phenotype of hyperuricemia mice.

[0060] Table 3. Statistical table of serum inflammatory indicators in each group

[0061] Group IL-1β (ng / L) IL-6 (ng / L) TNF-α (ng / L) Blank control group (Control) 83.58±2.20 111.20±2.64 740.60±8.96 Model <![CDATA[103.50±2.29 *** ]]> <![CDATA[134.40±1.44 **** ]]> <![CDATA[987.20±26.07 **** ]]> Compound low-dose group (FL) 93.44±3.20 <![CDATA[123.50±3.14 △ ]]> 906.70±24.83 Compound high-dose group (FH) <![CDATA[89.83±2.58 △ ]]> <![CDATA[122.00±1.69 △△ ]]> <![CDATA[806.70±16.02 △△△△ ]]> Allopurinol group (AP) 94.43±3.42 <![CDATA[117.60±2.44 △△△ ]]> <![CDATA[817.90±21.05 △△△△ ]]>

[0062] Note: Compared with the blank group: *** P<0.001, **** P<0.0001; compared with the model group:△ P<0.05, △△ P<0.01, △△△ P<0.001, △△△△ P<0.0001.

[0063] (2) Immunohistochemical staining results (F4 / 80)

[0064] like Figure 2 As shown in Table 4, compared with the blank group mice, the expression of F4 / 80 in the kidney of the model group mice was significantly increased, and the compound administration significantly reduced the macrophage infiltration in the kidneys of hyperuricemia mice in a dose-dependent manner.

[0065] Table 4. Statistics of F4 / 80 positive areas in kidneys of each group

[0066] Group Positive area (%) Blank control group (Control) 0.1550±0.0232 Model <![CDATA[2.8040±0.2835 **** ]]> Compound low-dose group (FL) <![CDATA[1.3340±0.3430 △△ ]]> Compound high-dose group (FH) <![CDATA[0.6463±0.1167 △△△ ]]> Allopurinol group (AP) <![CDATA[0.7627±0.1145 △△△ ]]>

[0067] Note: Compared with the blank group: **** P<0.0001; compared with the model group: △△ P<0.001, △△△ P<0.001.

[0068] 4. Reduce renal fibrosis in mice with high uric acid levels

[0069] (1) Masson staining results

[0070] The results are as follows Figure 3 As shown in Table 5, the collagen deposition in the model group was significantly higher than that in the blank group, while the collagen deposition in each drug-treated group was significantly reduced, indicating that the compound can significantly reduce renal fibrosis in hyperuricemia mice.

[0071] Table 5. Statistics of kidney collagen deposition area in each group

[0072] Group area(%) Blank control group (Control) 1.832±0.301 Model 18.900±3.689*** Compound low-dose group (FL) <![CDATA[4.130±0.551 △△△ ]]> Compound high-dose group (FH) <![CDATA[3.666±0.106 △△△ ]]> Allopurinol group (AP) <![CDATA[2.041±0.409 △△△ ]]>

[0073] Note: Compared with the blank group: *** P<0.001; compared with the model group: △△△ P<0.001.

[0074] (2) Immunohistochemical staining results (Fibronectin)

[0075] like Figure 4 As shown in Table 6, compared with the blank group mice, the expression of Fibronectin (FN) in the kidney of the model group mice was significantly increased. After administration of the compound, the expression of FN in the kidney of the hyperuricemia mice was significantly reduced in a dose-dependent manner, indicating that the compound can improve renal fibrosis in hyperuricemia mice.

[0076] Table 6. Statistics of FN-positive areas in kidneys of each group

[0077] Group Positive area (%) Blank control group (Control) 0.277±0.021 Model <![CDATA[3.267±0.142 **** ]]> Compound low-dose group (FL) <![CDATA[1.226±0.436 △△△ ]]> Compound high-dose group (FH) <![CDATA[0.335±0.034 △△△△ ]]> Allopurinol group (AP) <![CDATA[0.309±0.061 △△△△ ]]>

[0078] Note: Compared with the blank group: **** P<0.0001; compared with the model group: △△△ P<0.001, △△△△ P<0.0001.

[0079] (3) Immunohistochemical staining results (α-SMA)

[0080] like Figure 5 As shown in Table 7, compared with the blank group mice, the expression of α-SMA in the kidney of the model group mice was significantly increased, and the compound administration significantly reduced the expression of this protein in the kidney of hyperuricemia mice, indicating that the compound can improve renal fibrosis in hyperuricemia mice.

[0081] Table 7. Statistical table of α-SMA positive area in kidney of each group

[0082] Group Positive area (%) Blank control group (Control) 0.167±0.034 Model <![CDATA[2.382±0.258 **** ]]> Compound low-dose group (FL) <![CDATA[0.840±0.084 △△△△ ]]> Compound high-dose group (FH) <![CDATA[0.350±0.021 △△△△ ]]> Allopurinol group (AP) <![CDATA[0.287±0.023 △△△△ ]]>

[0083] Note: Compared with the blank group: **** P<0.0001; compared with the model group: △△△△ P<0.0001.

[0084] 5. Liver function test results

[0085] like Figure 6 Liver HE staining showed no significant liver lesions among the mice in each group. However, serum ALT and AST levels were significantly elevated in the model and positive drug groups (see Table 8). There was no significant difference between the compound group and the blank group, and both showed a downward trend compared to the model and positive drug groups. This suggests that the positive drug allopurinol can cause some liver damage, while the compound has a certain liver-protective effect.

[0086] Table 8. Statistical table of liver function indicators of mice in each group

[0087] Group ALT(U / L) AST(U / L) Blank control group (Control) 3.16±0.49 10.35±1.13 Model <![CDATA[6.09±0.59 * ]]> <![CDATA[16.19±1.01 * ]]> Compound low-dose group (FL) 4.14±0.72 14.56±1.00 Compound high-dose group (FH) 4.08±0.63 14.23±1.48 Allopurinol group (AP) <![CDATA[6.94±0.51 *** ]]> <![CDATA[16.61±2.09 * ]]>

[0088] Note: Compared with the blank group: * P<0.05, ** P<0.01.

Claims

1. A Chinese medicine composition for preventing or treating hyperuricemia, characterized in that: The invention is prepared from the following ingredients in the following weight ratio: 3-30 parts of thistle, 1-20 parts of gardenia, 1-20 parts of bamboo leaves, 3-20 parts of angelica, 3-30 parts of lily, 1-20 parts of corn silk, 0.1-20 parts of broccoli seed extract and 1-30 parts of eucommia leaves.

2. The Chinese medicine composition according to claim 1, characterized in that: The invention is prepared from the following ingredients in the following weight ratio: 4.5 parts of thistle, 3 parts of gardenia, 3 parts of bamboo leaves, 3 parts of angelica, 4.5 parts of lily, 3 parts of corn silk, 3 parts of broccoli seed extract and 6 parts of eucommia leaves.

3. The method for preparing the Chinese medicine composition according to claim 1 or 2, characterized in that: The method comprises the following steps: adding water to thistle, gardenia, bamboo leaf, angelica, lily, corn silk and eucommia leaf, heating under reflux for extraction twice, filtering, combining the extracts, drying and crushing, and mixing with broccoli seed extract for standby use.

4. The preparation method according to claim 3, characterized in that: During the extraction process, the mass-to-volume ratio of the material to the liquid (g / mL) was 1:3 to 1:20; each extraction time was 1 to 3 hours.

5. The preparation method according to claim 4, characterized in that: The mass-to-volume ratio of the material to the liquid (g / mL) was 1:10; each extraction time was 1 h.

6. Use of the traditional Chinese medicine composition according to claim 1 or 2 or the traditional Chinese medicine composition prepared by the method according to any one of claims 3 to 5 in the preparation of a medicament for treating or preventing hyperuricemia and / or hyperuricemia-induced renal injury.

7. A drug for treating or preventing hyperuricemia and / or hyperuricemia-induced renal injury, characterized by: The effective component is the traditional Chinese medicine composition according to claim 1 or 2 or the traditional Chinese medicine composition prepared by the method according to any one of claims 3 to 5.

8. The drug according to claim 7, characterized in that: The medicament further includes pharmaceutically acceptable adjuvants.

Images